Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fulcrum Therapeutics, Inc. (Nasdaq: FULC) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fulcrum is a clinical-stage biopharmaceutical company focused on small-molecule modulation of gene expression for genetically defined rare diseases, with its lead program pociredir in sickle cell disease.
Through this page, readers can access current reports on Form 8-K in which Fulcrum reports material events. Recent 8-K filings describe quarterly financial results, initial and updated data from the Phase 1b PIONEER trial of pociredir in sickle cell disease, and an underwriting agreement for a public offering of common stock and pre-funded warrants. Other 8-Ks cover items such as updated corporate presentations, annual meeting voting results, and stockholder advisory votes on executive compensation.
Fulcrum’s filings also reference its shelf registration statement on Form S-3, under which it has conducted underwritten public offerings, and detail the terms of pre-funded warrants, lock-up agreements, and related underwriting arrangements. As a Nasdaq-listed issuer, Fulcrum files periodic reports and maintains registration of its common stock under Section 12(b) of the Exchange Act.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain the key points of lengthy filings in plain language. Users can quickly see what each 8-K, registration statement, or related exhibit means for topics such as clinical trial updates, capital-raising transactions, and governance matters. Real-time ingestion from EDGAR helps ensure that new Fulcrum filings, including future annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 when available, are surfaced promptly with concise AI insights to support further research.
Fulcrum Therapeutics, Inc. reported a stock option grant to its Principal Accounting Officer, Greg Tourangeau. On February 2, 2026, he received a stock option (right to buy) covering 57,000 shares of common stock at an exercise price of $10.72 per share.
The option is scheduled to vest in equal quarterly installments over four years, beginning on the vesting commencement date of January 1, 2026, contingent on his continued service on each vesting date. Following this grant, he beneficially owns 57,000 derivative securities directly.
Fulcrum Therapeutics, Inc. reported a new equity award to its President and Chief Executive Officer, Alex Sapir. On February 2, 2026, Sapir received a stock option to buy 650,000 shares of Fulcrum common stock at an exercise price of $10.72 per share.
The option is scheduled to vest in equal quarterly installments over four years, beginning on the vesting commencement date of January 1, 2026, and depends on Sapir’s continued service on each vesting date. Following this grant, Sapir beneficially owns 650,000 derivative securities directly.
Fulcrum Therapeutics, Inc. reported a preliminary estimate of approximately $352.3 million in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is based on management’s estimates, is unaudited, and may change as year-end financial closing procedures are completed.
The company also released an updated corporate presentation with business and strategic updates, which it plans to use in investor meetings, including a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is available via webcast and as an exhibit to this report.
Fulcrum Therapeutics director Robert J. Gould reported a planned sale of company stock. On January 2, 2026, he sold 15,000 shares of Fulcrum Therapeutics common stock at a weighted average price of $11.8726 per share, with individual trade prices ranging from $10.60 to $11.33. These transactions were carried out under a Rule 10b5-1 trading plan that he adopted on August 1, 2025. After this sale, he beneficially owned 469,864 shares of Fulcrum Therapeutics common stock, held directly.
Fulcrum Therapeutics, Inc. Chief Legal Officer Curt Oltmans reported a small stock sale under a pre-arranged trading plan. On 12/15/2025, he sold 3,452 shares of Fulcrum Therapeutics common stock at a price of $12.92 per share, as shown in Table I of the filing.
The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025, which is designed to follow preset instructions. After this transaction, Oltmans beneficially owned 10,252 shares, including shares previously acquired through the company’s employee stock purchase plan.
Fulcrum Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 11,851,853 shares of common stock at $13.50 per share and pre-funded warrants to purchase up to 1,111,193 shares of common stock at $13.499 per warrant. The underwriters also have a 30-day option to buy up to 1,944,456 additional shares at the same price, less underwriting discounts and commissions.
All securities are being sold by Fulcrum, which expects to receive net proceeds of about $164.1 million, or about $188.1 million if the underwriters fully exercise their option, after fees and expenses. The pre-funded warrants have a $0.001 exercise price, are immediately exercisable, and include ownership limits generally capped at 19.99% of outstanding common stock and additional limits tied to Hart-Scott-Rodino antitrust thresholds.
The offering is being made under an effective shelf registration statement, with closing expected on or about December 11, 2025, subject to customary conditions. Fulcrum and its directors and executive officers have agreed to short lock-up periods restricting additional sales of common stock following pricing.
Fulcrum Therapeutics director reports sale of common stock under trading plan. A reporting person serving as a director of Fulcrum Therapeutics, Inc. (FULC) sold 15,000 shares of common stock on 11/19/2025 in an open market transaction at a weighted average price of $11.033 per share. After this sale, the individual beneficially owns 484,864 shares of Fulcrum common stock in direct form. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on August 1, 2025, which is intended to allow systematic selling according to preset instructions.
Fulcrum Therapeutics (FULC) filed its Q3 2025 10‑Q, reporting continued operating focus on sickle cell candidate pociredir alongside tighter expenses. The quarter showed a net loss of $19.6 million on operating expenses of $21.9 million (R&D $14.3 million; G&A $7.6 million). Cash, cash equivalents, and marketable securities totaled $200.6 million as of September 30, 2025, and management states this should fund operations for at least 12 months from issuance. The accumulated deficit was $573.9 million.
Clinical update: In the 12 mg Phase 1b cohort (n=16), pociredir increased mean absolute fetal hemoglobin (HbF) by 8.6% at 12 weeks (7.6% to 16.2%); 7 of 16 exceeded 20% HbF. Hemolysis markers improved and mean hemoglobin rose by 0.9 g/dL. Safety was generally well-tolerated with no drug‑related serious adverse events or discontinuations. Enrollment in the 20 mg cohort (n=12) is complete, with data expected by the end of 2025.
There was no collaboration revenue in Q3 2025 (vs. $80.0 million in the first nine months of 2024 from a now-terminated Sanofi agreement). Shares outstanding were 54,118,438 as of October 22, 2025.
Fulcrum Therapeutics (FULC) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025. A detailed press release was furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information, including the exhibit, is furnished and not deemed filed under the Exchange Act. Fulcrum’s common stock trades on the Nasdaq Global Market under the symbol FULC.
Fulcrum Therapeutics, Inc. furnished an updated corporate presentation dated August 28, 2025 that may be used at conferences and investor meetings. The presentation is available in the Events and Presentations section of the company’s website and is attached as Exhibit 99.1. Fulcrum specifies that this material is provided under Regulation FD and is considered “furnished” rather than “filed,” which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.